Loading...
Market
How will GSK's lupus drug affect its market share in autoimmune treatments by 2026?
2
Resolution / Starting Odds
Increase by over 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No significant change • 25%
Industry market reports and GSK financial statements
Story
GSK Acquires Investigational Lupus Drug from Chimagen Biosciences for $850 Million
Oct 29, 2024, 12:13 PM
GSK has announced the acquisition of an investigational drug from Chinese biotech firm Chimagen Biosciences for up to $850 million. This move aims to enhance GSK's pipeline of potential treatments for lupus, addressing ongoing unmet needs in autoimmune diseases. The acquisition reflects GSK's strategy to expand its portfolio in the competitive biopharmaceutical market, particularly in the area of autoimmune disorders.
View original story
Similar markets
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Below 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Above 30% • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Other • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Successful market introduction • 25%
Delayed market introduction • 25%
Project discontinued • 25%
Acquisition divested • 25%
